机构简介： 上海石锋资产管理有限公司成立于2015年，实缴资本1000万元，协会观察会员，具备"3+3"投顾资格， 已获四大报股票策略全满贯：2座中国证券报金牛奖，2座上海证券报金阳光奖，2座证券时报金长江 奖，2座中国基金报英华奖，还包括金樟奖，金鼎奖，东方财富，好买基金，金斧子，Wind等多项大 奖。公司多位合伙人均在大型保险、券商资管、公募基金从事投研工作十年以上。公司专注二级市场股 票投资，与国内知名银行、券商、第三方均有合作，旨在为客户创造长期稳健复利。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 1）上海家化 （上海石锋资产管理有限公司参与公司业绩说明会） 调研纪要：上海家化对618有信心，核心品牌有望实现高双位数GMV增长。员工持股计划旨在提高竞争 力、降低流失率、养成主人翁精神。过去半年进行了战略明确、组织设计匹配、人才队伍建设、文化建 设等调整。电商方面进行了货盘梳理、价盘整理、组织架构调整和产品迭代。玉泽B5系列计划作为京 东阵地主要产品线。效率提升方面，品效、人效、电商服务、经营质量均有提升。今年营收力争两位 ...

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover rates, and foster a sense of ownership among employees [1] - The company has made strategic adjustments in the past six months, including organizational design, talent development, and cultural initiatives [1] - E-commerce strategies have been refined, including inventory management, pricing adjustments, organizational restructuring, and product iterations [1] - The Yuze B5 series is planned to be a key product line on JD.com [1] - The company aims for double-digit revenue growth this year and to turn profits around [1] - The long-term profit recovery is expected to follow a timeline of 1-2 years for revenue growth, 2-3 years for profit improvement, and 3-5 years to meet profit margin targets [1] - The main brand Yuze is positioned as a skin barrier repair expert, while Liushen is expanding its usage scenarios and target demographics [1] Group 2: Zai Lab - Zai Lab introduced its pipeline drugs ZG006, ZG005, and ZGGS18, highlighting their latest developments and future plans for the next 3-5 years [2] - ZG006 is the world's first DLL3-expressing tumor tri-specific antibody, which has received clinical trial approvals from NMPA and FDA, showing promising early efficacy [2] - ZG005 is one of the first drugs in clinical research targeting the same pathway, with multiple clinical studies underway [2] - ZGGS18 has completed the dose escalation in Phase I trials in China and is currently in Phase I/II clinical trials [2] - The company plans to continuously explore the commercialization potential of its existing and upcoming products to achieve sustained revenue growth [2] - Zai Lab also discussed the sales progress and future expectations for recombinant human thrombin and the approval status of recombinant human thyroid-stimulating hormone [2] Group 3: Company Overview - Shenzhen Zhongou Ruibo Investment Management Co., Ltd. was established in 2007 and is one of the earliest private equity fund management companies in China [3] - The company focuses on secondary market securities investment and has launched over 50 private equity products in collaboration with top domestic financial institutions [3] - It obtained private fund manager qualifications in 2014 and launched its first overseas fund in 2016 [3] - The name "Rabbit Fund" reflects the company's investment culture of risk management, emphasizing the importance of risk prevention and management [3] - The investment philosophy is centered on growing alongside great companies and adapting strategies to respect market trends [3] - The company has received numerous accolades for its performance, including the "Morningstar Award" and "Golden Bull Award" [3]

根据市场公开信息及4月28日披露的机构调研信息，知名私募重阳投资近期对2家上市公司进行了调研， 相关名单如下： 1）上海家化 （上海重阳投资管理股份有限公司参与公司业绩说明会） 调研纪要：上海家化对618有信心，核心品牌有望实现高双位数GMV增长。员工持股计划旨在提高竞争 力、降低流失率、养成主人翁精神。过去半年进行了战略明确、组织设计匹配、人才队伍建设、文化建 设等调整。电商方面进行了货盘梳理、价盘整理、组织架构调整和产品迭代。玉泽B5系列计划作为京 东阵地主要产品线。效率提升方面，品效、人效、电商服务、经营质量均有提升。今年营收力争两位数 增长，利润扭亏为盈。驱蚊蛋将加大线上布局，线下分销铺货。长期盈利修复节奏为1-2年看营收增 长，2-3年盈利提升，3-5年利润率达标。主要品牌玉泽定位皮肤屏障修护专家，六神拓展使用场景和人 群。 2）英杰电气 （上海重阳投资管理股份有限公司参与公司特定对象调研） 调研纪要：2024年英杰电气营收17.8亿元，同比增长0.59%，归母净利润下降25.19%。光伏行业收入确 认延缓、发出商品计提存货跌价准备及期间费用增加导致业绩未达预期。经营活动现金流净流量为 60,176 ...

根据市场公开信息及4月28日披露的机构调研信息，知名私募彤源投资近期对4家上市公司进行了调研， 相关名单如下： 调研纪要：芯碁微装在先进封装领域取得进展，设备WLP2000完成多家客户验证，部分进入量产筹 备。直写光刻技术在无掩膜成本及操作便捷等方面具备优势。关税政策对公司影响有限，供应链结构优 化，客户订单持续增长。泰国子公司以服务本土客户为核心，已有20多名员工，本地与外派人员各半。 2024年海外订单占比接近20%，彰显国际市场竞争力。掩模板业务预计今年下半年迎来突破，2026- 2027年占据有利地位。去年IC载板业务面临挑战，但对2025-2026年发展前景充满信心。一季度营业收 入同比增加22.31%，净利润同比增加30.45%，销售量规划充满信心。 4）康弘药业 （上海彤源投资发展有限公司参与公司电话会议&口头） 调研纪要：康柏西普已稳居中国眼科抗VEGF市场的领导地位，公司有信心继续取得新辉煌。公司整体 研发布局集中在眼科、精神/神经、肿瘤领域，形成多元化研发体系。基因治疗产品显示良好安全性和 疗效，双载荷DC分子具有协同作用。公司积极应对集采政策，创新药销售占比提升，化药仿制药销售 占比下降 ...

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover, and foster a sense of ownership among employees [1] - Recent strategic adjustments include clarifying strategy, aligning organizational design, building talent teams, and cultural development [1] - E-commerce initiatives involve inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The Yuze B5 series is planned as a key product line for JD.com [1] - The company aims for double-digit revenue growth this year and to turn profits around [1] - The long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Zai Lab - Zai Lab introduced its pipeline drugs ZG006, ZG005, and ZGGS18, highlighting their latest progress and future plans for R&D, commercialization, and internationalization over the next 3-5 years [2] - ZG006 is the world's first DLL3-expressing tumor tri-specific antibody, which has received clinical trial approval from NMPA and FDA, showing promising early efficacy [2] - ZG005 is among the first drugs in clinical research targeting the same pathway, with multiple clinical studies ongoing [2] - ZGGS18 has completed the I phase dose escalation in China and is currently in I/II phase clinical trials [2] - The company plans to continuously explore the commercialization potential of its existing and upcoming products to achieve sustained revenue growth [2] Group 3: Aladdin - Aladdin has achieved several domestic product replacements through independent R&D and innovation, enhancing its competitive edge [3] - The company collaborates with Yuan Ye and Fei Peng to share resources, expand business scale, and improve overall competitiveness [3] - Cost control measures include promoting convertible bond conversions, optimizing inventory turnover, and expanding overseas markets and biological reagent business [3] - Revenue growth in the life sciences sector is primarily driven by the merger with Yuan Ye Bio, increasing sales of major life science products [3] - Both external and internal growth strategies are driving the company's development, with active research into potential acquisition projects [3] Group 4: Company Overview - Shanghai Licheng Asset is one of the earliest established private equity management companies in China, focusing on growth stock investment with a safety margin approach [4] - The company has a complete and unique investment management knowledge system, with a team of 50 employees, nearly 30 of whom are professional research analysts [4] - The management scale has exceeded 10 billion yuan, specializing in secondary stock long strategies and PIPE strategies in the pharmaceutical, advanced manufacturing, and consumer sectors [4] - Licheng has consistently ranked high in long-term performance and has received multiple private equity awards [4]